AGE Levels in ER+ Metastatic Breast Cancer Patients Receiving Endocrine Therapy

Breast Cancer Clinical Trial

Official title:

Pilot Study of Pharmacologic Manipulation of AGE (Advanced Glycation Endproducts) Levels in ER+, Metastatic Breast Cancer Patients Receiving Endocrine Therapy

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03092635
• Other study ID #: 102560
• Status: Terminated
• Phase: Phase 1
• Start date: June 6, 2017
• Est. completion date: April 22, 2022

Study information

• Verified date: August 2022
• Source: Medical University of South Carolina
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to look at the effects that the study drug (OPC) has on AGE levels in patients with ER+ metastatic breast cancer.

Description:

AGEs are a type of metabolite, or substance, found in the food. The AGE content in food is determined by the types of food you eat and also how you prepare your food. The researchers helping conduct this study have found a potential link between AGE levels and cancer. The purpose of this study is to see if certain drug (OPC) has an effect on the AGE levels in your blood and to see if those AGE levels have an effect on your cancer.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 9
• Est. completion date: April 22, 2022
• Est. primary completion date: November 10, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Must have ER+ breast cancer

• Metastatic disease; protocol does allow for bone-only disease

• Must be receiving endocrine therapy

• Must have completed at last 2 months of current endocrine therapy prior to registration

• Must have adequate hematologic, renal and hepatic function

• Prior/concurrent radiation therapy is allowed

• Prior chemotherapy is allowed, but last dose must have been at least 2 months prior to enrollment

• May have diabetes, but must not be taking metformin

• Must be able to swallow and retain oral medication

• Performance status of 0-2

• Treated stable brain metastases are allowed, as long as patient does not require steroids or anti-seizure medications

• Must be informed of the investigational nature of this study and must have the ability to sign informed consent.

Exclusion Criteria:

• Known allergy to grapes or grape seed

• More than two prior endocrine therapy regimens for the treatment of metastatic ER+ breast cancer.

• Concurrent use of restricted agents outlined in section 4.5.

• History of alcohol abuse within 2 years of registration.

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Drug:
• OPC
OPC is a derivative of grape seed extract

Locations

Country	Name	City	State
United States	Medical University of South Carolina	Charleston	South Carolina

Sponsors (1)

Lead Sponsor	Collaborator
Medical University of South Carolina

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	AGE level reduction	The primary objective is to determine if the test agents are able to reduce AGE levels by at least 30% in th 50% or more of test subjects.	85 days
Secondary	Correlation between AGE level and changes to BMI	Changes in AGE levels and BMI will be described using graphs and other models.	85 days
Secondary	Correlation between AGE level and insulin resistance (HOMA-IR)	Changes in AGE levels and HOMA-IR will be described using graphs and other models.	85 days
Secondary	Correlation between AGE level and A1C	Changes in AGE levels and A1C will be described using graphs and other models.	85 days
Secondary	Correlation between AGE level and lipids	Changes in AGE levels and lipids will be described using graphs and other models.	85 days
Secondary	Correlation between AGE level and diet	Changes in AGE levels and diet will be described using graphs and other models. Diet will be assessed by using the NIH "Eating at America's Table Study Quick Food Scan" and the NCI "Quick Food Scan"	85 days
Secondary	Correlation between AGE level and quality of life	Measured by FACT-B quality of life questionnaire	85 days
Secondary	Correlation between AGE level and plasma IL6	Changes in AGE levels and IL6 will be described using graphs and other models.	85 days
Secondary	Correlation between AGE level and leptin	Changes in AGE levels and leptin will be described using graphs and other models.	85 days
Secondary	Correlation between AGE level and c-reactive protein (CRP)	Changes in AGE levels and CRP will be described using graphs and other models.	85 days
Secondary	Correlation between AGE level and malondialdehyde (MDA)	Changes in AGE levels and MDA will be described using graphs and other models.	85 days
Secondary	Correlation between AGE level and oxLDLs (low density lipoprotein)	Changes in AGE levels and oxLDLs will be described using graphs and other models.	85 days
Secondary	Correlation between AGE level and sRAGE (soluble receptor for AGE)	Changes in AGE levels and sRAGE will be described using graphs and other models.	85 days
Secondary	Frequency of adverse events as assessed by CTCAE v. 4	Toxicities will be tabulated by type, grade and the visit at which they occurred.	85 days
Secondary	Tumor response to treatment as assessed by RECIST 1.1 or MD Anderson criteria	The anti-tumor response will be measured by comparing baseline and post-treatment imaging using RECIST 1.1 or MD Anderson criteria for bone only disease.	85 days